ライフサイエンスコーパス: allograft survival

1 led to HSC mobilization and prolonged islet allograft survival.

2 at CD27low but not CD27high NK cells enhance allograft survival.

3 hypothesis that ApoE(133-149) promotes renal allograft survival.

4 changes affect T cell fate and subsequently allograft survival.

5 ry will be essential for improving long-term allograft survival.

6 ntain adequate immunosuppression and prolong allograft survival.

7 ponsible of the maintenance of the long-term allograft survival.

8 splant, sex, donor type, induction agent) on allograft survival.

9 -dependent suppressive function and impaired allograft survival.

10 means for enhancing therapeutic results and allograft survival.

11 networks of new regulatory cells to maintain allograft survival.

12 enger leukocytes significantly prolongs lung allograft survival.

13 noregulatory IL-10 associated with prolonged allograft survival.

14 ammatory kidney injury and promote long-term allograft survival.

15 CD11c(+) T cells and significantly prolonged allograft survival.

16 effect of PI3Kdelta inhibition on long-term allograft survival.

17 ptide resulted in indefinite prolongation of allograft survival.

18 peak viral load, rejection, and patient and allograft survival.

19 chanism of immune regulation in MSC-mediated allograft survival.

20 ssion may be a viable strategy for promoting allograft survival.

21 ted T cell depletion markedly prolonged skin allograft survival.

22 n between infiltration of memory T cells and allograft survival.

23 revention of IRI and significantly prolonged allograft survival.

24 ls from B7-H4 transgenic mice enhances islet allograft survival.

25 ltrating T cells and significantly prolonged allograft survival.

26 t serve as a tool to improve long-term renal allograft survival.

27 ation with cyclosporin A had prolonged renal allograft survival.

28 rt-term allograft outcomes but not long-term allograft survival.

29 ds ratio, 11.4, P=0.001), and a lower 5-year allograft survival.

30 is associated with a 3-fold prolongation in allograft survival.

31 lications for both assays to improve overall allograft survival.

32 infection events (MIE) can reduce long-term allograft survival.

33 at early times after engraftment may predict allograft survival.

34 ferret with documented long-term functional allograft survival.

35 id not result in significant prolongation of allograft survival.

36 enic mice increases skin, cardiac, and renal allograft survival.

37 tion is a significant barrier to small bowel allograft survival.

38 transplant dysfunction and improve long-term allograft survival.

39 s well tolerated and induced long-term islet allograft survival.

40 nts exhibit indefinite prolongation of heart allograft survival.

41 anent, T cell-poor, mixed-chimerism on renal allograft survival.

42 ejection with antibiotics may improve kidney allograft survival.

43 ere no significant differences in patient or allograft survival.

44 erging evidence for epigenetic influences on allograft survival.

45 tory cytokines and chemokines, which promote allograft survival.

46 increased morbidity, mortality, and reduced allograft survival.

47 art transplant model, they promote long-term allograft survival.

48 rejection (AMR) and significantly compromise allograft survival.

49 offer opportunities to optimize ideal renal allograft survival.

50 ill be more effective in maintaining corneal allograft survival.

51 memory B cells have been linked to decreased allograft survival.

52 n CDK2-deficient recipients led to long-term allograft survival.

53 of novel interventions to improve long-term allograft survival.

54 t of CD4(+) T cell dysfunction and long-term allograft survival.

55 hazard ratios for overall and death-censored allograft survival.

56 bility of aged recipients to achieve maximal allograft survival.

57 a novel therapeutic target for improving SIT allograft survival.

58 i-CM antibody titers, demonstrated long-term allograft survival.

59 ) Tregs that underlie IL-33-mediated cardiac allograft survival.

60 is in the islets and significantly prolonged allograft survival.

61 mulatory blockade-based therapies to prolong allograft survival.

62 tribution of regulatory T cells to prolonged allograft survival.

63 Tregs) respond to IL-17A and enhance corneal allograft survival.

64 at depletion of IL-17A would enhance corneal allograft survival.

65 ymphangiogenesis and prolonged or indefinite allograft survival.

66 onor-specific chimerism, in correlation with allograft survival.

67 s rather than Ag-presenting cells to prolong allograft survival.

68 ransplants hampers improvements in long-term allograft survival.

69 ogic AMR reversal influences long-term renal allograft survival.

70 egulation may thus be effective in promoting allograft survival.

71 to promote tolerance induction and long-term allograft survival.

72 s may enhance rejection and affect long-term allograft survival.

73 ed rejection (AMR) is a major risk for renal allograft survival.

74 t infiltration and improve long-term corneal allograft survival.

75 ant recipients and results in improved renal allograft survival.

76 ell proliferation and only modestly prolongs allograft survival.

77 administration on Treg function and corneal allograft survival.

78 ge have independent adverse effects on renal allograft survival.

79 tragraft accumulation of Tregs and prolonged allograft survival.

80 dy-mediated rejection is a serious threat to allograft survival.

81 nsplants, analyzing 3-year patient and renal allograft survival.

82 age (HR, 0.70; P = 0.001) adversely impacted allograft survival.

83 CD3-NK1.1(+) cells in the liver and prolongs allograft survival.

84 ansplantation is a risk factor for decreased allograft survival.

85 CNIs) have failed to improve long-term renal allograft survival.

86 ne the impact of HLA compatibility on kidney allograft survival.

87 Regulatory T cells (Tregs) are crucial for allograft survival.

88 n leucocyte antigen (HLA) matching in kidney allograft survival.

89 s the effect of anti-E-selectin on long-term allograft survival.

90 allograft leading to infections and reduced allograft survival.

91 he allograft and the impact of recurrence on allograft survival.

92 dritic cell recruitment to promote long-term allograft survival.

93 h stable IDO-expressing fibroblasts prolongs allograft survival.

94 A)-1 in organ transplant recipients prolongs allograft survival.

95 ew therapeutic strategy to enhance long-term allograft survival.

96 hat, ultimately, may improve long-term renal allograft survival.

97 nzyme inhibitor also significantly prolonged allograft survival (12 versus 7 days; P<0.0001).

98 livered by lentiviral vector prolonged islet allograft survival (51.0 +/- 2.9 days) by increasing the

99 or 1.0 mg/kg KRP203 produced long-term islet allograft survival (9200 days) in one of five and two of

100 associated nephropathy is a threat to kidney allograft survival affecting up to 15% of renal transpla

101 the last few decades, strategies to improve allograft survival after kidney transplantation have bee

102 Allograft survival after kidney transplantation is signi

103 matic improvements in short-term patient and allograft survival after kidney transplantation.

104 significance of humoral immune response for allograft survival after liver transplantation (LT) is s

105 Allograft survival after PTLD diagnosis was 94.4% (66.6-

106 Among these 82 patients, pancreatic allograft survival after renal retransplantation was 78%

107 Although short-term allograft survival after solid organ transplantation has

108 remains a major clinical challenge limiting allograft survival after solid organ transplantation.

109 Overall, allograft survival analysis revealed a survival advantag

110 is the most important determinant of cardiac allograft survival and a major cause of death after hear

111 tions in vivo and have beneficial effects on allograft survival and autoimmune diseases.

112 -specific pan-Notch blockade prolonged heart allograft survival and decreased IFN-gamma and IL-4 prod

113 apamycin achieved long-term pancreatic islet allograft survival and donor-specific tolerance in a mou

114 attenuated in TLR4 mice; however, long-term allograft survival and function were not affected in our

115 iated with significant reduction in pancreas allograft survival and impact resource use.

116 rging phenomenon that may decrease long-term allograft survival and impair allograft function.

117 ciated severe arteriosclerosis had decreased allograft survival and increased mortality (P<0.0001); t

118 ted through IL-22 production, which enhances allograft survival and increases insulin secretion.

119 nosuppression allows prolongation of cardiac allograft survival and one tolerant recipient.

120 B cells have been associated with long-term allograft survival and operational tolerance, memory B c

121 This enhanced allograft survival and protolerogenic skewing of the all

122 onses because they are known to promote both allograft survival and rejection.

123 (Tregs) have been associated with prolonged allograft survival and tolerance across a wide variety o

124 eceased and living organ donation, improving allograft survival and unmet clinical needs in organ tra

125 alysis was performed for PTLD-free survival, allograft survival, and patient survival after PTLD.

126 etween CIT and delayed graft function (DGF), allograft survival, and patient survival for 1267 shippe

127 Perioperative complications, allograft survival, and patient survival were similar be

128 scular morbidity and mortality and shortened allograft survival are important consequences of inadequ

129 The implications of this policy for kidney allograft survival are not well understood.

130 to entrain a long-term response favorable to allograft survival as part of an immunomodulatory regime

131 Prolonged allograft survival associated with DCreg infusion may be

132 ving a DCD kidney transplant have good renal allograft survival at 3-year follow-up, comparable to th

133 Kidney allograft survival at 5 years was 83.6% for T1DM, 80.4%

134 ve kidney disease, there is no difference in allograft survival at 5-year posttransplant for recipien

135 Allograft survival averaged 5.9+/-2.9 weeks (n=10) in MR

136 as no significant difference in 3-year renal allograft survival between the DCD and DBD groups (P = 0

137 There was no difference in allograft survival between the TRAS+ intervention and TR

138 groups, p = 0.12; there was a difference in allograft survival between the TRAS- and TRAS+ noninterv

139 cific; 5) Tregs are not required for corneal allograft survival beyond day 30; and 6) corneal allogra

140 gatively affect intermediate-term patient or allograft survival but is associated with increased risk

141 ass is an important determinant of long-term allograft survival, but accurate assessment before organ

142 -specific HLA antibodies significantly lower allograft survival, but as yet there are no satisfactory

143 inhibitory FcgammaRIIb may therefore prolong allograft survival, but its role in transplantation has

144 analysis revealed that APOL1 impacted renal allograft survival, but not recipient survival.

145 s study was to explore prolongation of islet allograft survival by cotransplantation with myeloid-der

146 Therefore, SHS prevents long-term allograft survival by inhibiting IDO expression and acti

147 ndostatin plays an important role in corneal allograft survival by inhibiting neovascularization and

148 und that the CD27low NK cells restore better allograft survival by inhibiting the proliferation of al

149 s its neutralization significantly prolonged allograft survival by reducing intragraft expression of

150 ed the effect of HLA compatibility on kidney allograft survival by studying all first adult kidney tr

151 Expression of CD200 increases allograft survival by suppressing inflammation and acqui

152 +) cells, and significantly improved corneal allograft survival compared to saline-injected controls.

153 ns of ECDI-SPs significantly prolong cardiac allograft survival concomitant with an impressive accumu

154 ta cells from transgenic mice prolongs islet allograft survival, confirming the negative role of B7-H

155 Progress in long-term renal allograft survival continues to lag behind the progress

156 Long-term allograft survival correlated with development and maint

157 Allograft survival despite complete immunosuppressant wi

158 The in vivo findings in terms of allograft survival did not reflect superior immunomodula

159 Kaplan-Meier curves showed global allograft survival differences (P=0.042) mostly due to p

160 Corneal allograft survival dramatically decreases in hosts with

161 tion but does not appear to adversely impact allograft survival during the early follow-up period.

162 tion but does not appear to adversely impact allograft survival during the early follow-up period.

163 was associated with HLA mismatch and affects allograft survival even during the recent periods of inc

164 The higher transplant rates and allograft survival expected for candidates in the top 20

165 To detect other factors impacting allograft survival from deceased AA kidney donors, APOL1

166 Recipient age affects allograft survival from high-quality young DD kidneys, s

167 between patient survival and death-censored allograft survival (graft survival).

168 the time of transplant dramatically improved allograft survival (>100 d) over either agent alone (<30

169 alloantigens, and produced long-term cardiac allograft survival (>100 days) in 10 out of 11 recipient

170 ) recipients with CTLA4-Ig induced long-term allograft survival (>100 days) without histological sign

171 ) regulatory T cells (T(regs)) and long-term allograft survival (>300 days).

172 e association of HLA mismatching with kidney allograft survival has been well established.

173 nfidence interval [95% CI], 0.28 to 2.49) or allograft survival (HR, 0.80; 95% CI, 0.37 to 1.73) betw

174 de alone induced indefinite pancreatic islet allograft survival if anti-IL-7R treatment was started 3

175 rse of rapamycin provides indefinite cardiac allograft survival in 100% of the recipients.

176 C treatment resulted in long-term (>120 day) allograft survival in 47% of the animals, which correlat

177 he first time demonstrates that SHS shortens allograft survival in a cause-effect manner and unveils

178 monocytes in vitamin D3 and IL-10, on renal allograft survival in a clinically relevant rhesus macaq

179 dendritic cells (dexDCs) could prolong islet allograft survival in a full major histocompatibility co

180 odiimide (ECDI-SPs) induces indefinite islet allograft survival in a full MHC-mismatched model withou

181 ration in vitro and were all able to prolong allograft survival in a model of skin transplantation.

182 regs expanded in vivo by TNFRSF25 on cardiac allograft survival in a mouse model of fully major histo

183 hat lymphatic vessel formation improves lung allograft survival in a murine transplant model.

184 ibodies (DSA) is associated with worse renal allograft survival in adult patients.

185 kidney transplantation has acceptable renal allograft survival in adults but there are few data in p

186 tion abolishes this discrepancy and improves allograft survival in African American recipients.

187 ection has long-term consequences for kidney allograft survival in an observational prospective cohor

188 TIM-1(+) B cells prolonged islet allograft survival in B-deficient mice, whereas TIM-4(+)

189 resensitization on patient and overall renal allograft survival in CLK.

190 AA) recipient race are associated with worse allograft survival in deceased-donor kidney transplantat

191 0 costimulation is needed for long-term IPCC allograft survival in diabetic NOD mice.

192 hylcarbodiimide (ECDI-SPs) induces long-term allograft survival in full MHC-mismatched models of allo

193 the long-term effect of Gram-negative BSI on allograft survival in kidney transplant recipients.

194 moral tolerance and promotes long-term islet allograft survival in mice.

195 Cs that, when transfer systemically, prolong allograft survival in murine models.

196 ng T cell depletion confers an advantage for allograft survival in murine transplant models.

197 stimulation-blocker CTLA4Ig) prolonged islet allograft survival in nonhuman primates relative to cont

198 Our findings showed a prolonged allograft survival in older recipients associated with a

199 ry blockade-based treatment failed to extend allograft survival in older recipients to the same exten

200 and Fas/TNF signaling induced long-term IPCC allograft survival in overwhelming majority of recipient

201 nsplant registry data to compare patient and allograft survival in patients discharged from their ind

202 We evaluated the 15-year kidney allograft survival in patients with primary glomerulonep

203 ne prevents IRI and has beneficial effect on allograft survival in rat cardiac allografts.

204 een CD40 and CD40L induces long-term cardiac allograft survival in rats through a CD8+CD45RClo Treg p

205 taneous BMT and VCA may establish indefinite allograft survival in rats through Treg-mediated suppres

206 o the new 478 DDKTs replicated shorter renal allograft survival in recipients of APOL1 2-renal-risk-v

207 pt and sirolimus successfully prevents islet allograft survival in rhesus monkeys, but induction with

208 r without alefacept reliably prolonged renal allograft survival in rhesus monkeys.

209 was insufficient to markedly prolong cardiac allograft survival in sensitized BKO recipients.

210 ll expansion and significantly extends heart allograft survival in sensitized recipients.

211 significant improvement in long-term corneal allograft survival in the IL-2 treated group compared wi

212 by increased rejection or worsening patient/allograft survival in the short term.

213 Allograft survival in the TRAS+ intervention, TRAS+ noni

214 reports have documented unexplained reduced allograft survival in these patients.

215 Increased allograft survival in transgenic mice overexpressing CD2

216 revent alloimmunity and to improve long-term allograft survival in transplantation.

217 bits T cell proliferation in vitro, supports allograft survival in vivo, prevents corneal transplant

218 doptive transfer, significantly prolong skin allograft survival in vivo.

219 dritic cell density was associated with poor allograft survival independent of clinical variables.

220 tibody generation and significantly extended allograft survival, indicating that donor-specific alloa

221 nd hand smoke (SHS) hindered long-term islet allograft survival induced by CD154 costimulatory blocka

222 CD8+ Tmem is associated with prolonged renal allograft survival induced by DCreg infusion in CTLA4Ig-

223 further promoted HSC mobilization and islet allograft survival, inducing a robust and transferable h

224 site prognostic ABMR score to predict kidney allograft survival, integrating the disease characterist

225 Long-term allograft survival is a major challenge facing solid org

226 pacts costimulatory blockade induced cardiac allograft survival is not known.

227 Shorter renal allograft survival is reproducibly observed after DDKT f

228 lantation hyperglycemia with long-term renal allograft survival is unknown.

229 Islet allograft survival limits the long-term success of islet

230 To improve long-term kidney allograft survival, management paradigms should promote

231 ed ISDCs reduce the alloresponse and prolong allograft survival, not by themselves, but through conve

232 27low NK cells) show significantly prolonged allograft survival on costimulatory blockade when compar

233 nerated to assess differences in patient and allograft survival on the basis of BK viremia status; su

234 XM results did not influence patient or allograft survival, or cellular rejection rates, but XM+

235 opathy progression and may improve long-term allograft survival owing to favorable coronary remodelin

236 Px was not associated with kidney allograft survival (P = 0.16).

237 Q DSA was associated with a 30% lower 5-year allograft survival (P=0.003).

238 methotrexate together can provide long-term allograft survival potentially through the induction of

239 the 14 transplanted grafts, 1-year pancreas allograft survival rate was 100%.

240 Patients with TRIs had significantly lower allograft survival rates (50.9%) than patients without T

241 ntified three risk strata with 6-year kidney allograft survival rates of 6.0% (high-risk group, n=40)

242 jection was 9% at 1 year and the patient and allograft survival rates were 100% and 91%, respectively

243 The 1-, 3-, 5- and 7-year death-censored allograft survival rates were 98%, 91%, 86%, and 78%, re

244 howed significantly higher patient and liver allograft survival rates.

245 Long-term patient and allograft survival remains limited by cardiovascular dis

246 tes of acute transplant rejection, long-term allograft survival remains suboptimal.

247 pact of transplant center volume on pancreas allograft survival remains unclear.

248 ex vivo expanded human Treg prolonged islet allograft survival resulting in the accumulation of Treg

249 R/D BSA disparity was associated with worse allograft survival similar to the entire cohort (hazard

250 iogenic and immunological signals in corneal allograft survival, specifically the potential correlati

251 donor T cell responses, and prolonging heart allograft survival than the commonly used treatment at t

252 +) that regulates Tregs fate while promoting allograft survival that may have clinical applications i

253 ect of various immunosuppressive regimens on allograft survival that we have previously reported.

254 ls, NAD(+) was able to promote an impressive allograft survival through a robust systemic IL-10 produ

255 SC-induced MDSCs significantly extends islet allograft survival through iNOS-mediated T-cell inhibiti

256 tive allograft preservation method to extend allograft survival time.

257 In summary, mature CD27low NK cells promote allograft survival under costimulatory blockade conditio

258 ntly, there was no significant difference in allograft survival up to 10 years (hazard ratio, 0.98; 9

259 In African Americans, the mean allograft survival was 54.8+/-0.98, months with PVD vers

260 In non-African Americans, the mean allograft survival was 55.4+/-0.44 months with PVD versu

261 Mean allograft survival was 55.5+/-0.55 months in patients wi

262 Allograft survival was 59.73+/-0.13 months in African Am

263 Mean allograft survival was 60.97+/-0.67 months in non-Africa

264 and NM patients, respectively, while kidney allograft survival was 88% in M and 92% in NM groups.

265 h 4, respectively, and death-censored 4-year allograft survival was 94.8%, 95.4%, 94.5%, and 74.6%, r

266 Three-year renal allograft survival was 95.2% in the DCD group, 87.1% in

267 R score less than 13, 10-year death-censored allograft survival was 96% to 100% regardless of MFI (P

268 utic DCs in transplantation, prolongation of allograft survival was achieved using donor apoptotic MR

269 After BLyS neutralization, indefinite islet allograft survival was achieved.

270 The prolongation of allograft survival was associated with Th2 polarization

271 Furthermore, Tim4-/- allograft survival was associated with the infiltration

272 Long-term allograft survival was compared using Kaplan-Meier curve

273 Allograft survival was determined by fasting blood gluco

274 Long-term allograft survival was evaluated for up to 9 weeks using

275 A significant difference in allograft survival was identified between whites (n = 27

276 Islet allograft survival was investigated in streptozotocin-in

277 Skin allograft survival was monitored, and the proliferation,

278 Skin allograft survival was prolonged for up to 17.8+/-0.6 da

279 Islet allograft survival was prolonged in IkappaBalphaDeltaN-T

280 Although prolonged allograft survival was seen in many recipients of APOL1

281 Allograft survival was significantly prolonged in IL-17(

282 Death-censored allograft survival was similar in all groups except the

283 However, allograft survival was similar in eyes with and without

284 Overall allograft survival was similar in the DSA-SPA-positive a

285 Overall allograft survival was similar in the DSA-SPA-positive a

286 Liver allograft survival was superior among CLKT patients irre

287 Five-year renal allograft survival was superior for children receiving a

288 Five-year renal allograft survival was superior for children receiving a

289 Migration and allograft survival were also studied in splenectomized a

290 Overall, the patient and allograft survival were equivalent.

291 etween donor age and APOL1 genotype on renal allograft survival were nonsignificant.

292 Death-censored AMR-free and allograft survivals were significantly lower in C1q-dnDS

293 nt with KRP203 significantly prolonged islet allograft survival, whereas additional intragraft delive

294 Sensitized blacks had the lowest rate of allograft survival, whereas nonsensitized Asians had the

295 combinant EPO administration prolonged heart allograft survival, whereas pharmacologic downregulation

296 ostimulation with CD40Ig leads to indefinite allograft survival, which is mediated by the induction o

297 treated with ApoE(133-149) showed prolonged allograft survival, which was associated with a reduced

298 he success of future therapies in prolonging allograft survival will require an intimate understandin

299 onths, there was 100% (death-censored) renal allograft survival with estimated glomerular filtration

300 , 3A8-based therapy markedly prolonged islet allograft survival without depleting B cells.